Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16010669 | 0.99 | PTGS2 (0.52) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen Trelamine SCHEMBL30345799 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen Trelamine SCHEMBL2467991 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen Trelamine SCHEMBL30346084 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen Trelamine SCHEMBL25249124 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| Ibuprofen Trelamine SCHEMBL2575591 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL3824048 | 0.83 | PTGS2 (0.56) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL30116363 | 0.83 | PTGS2 (0.59) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL3823288 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1CXCR1CXCR2LMNA | |
| SCHEMBL30346098 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1CXCR1CXCR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962369-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9949952-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3116489-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | Yu, Benjamin M. (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2964231-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORMS OF SOLUTION OR SUSPENSION | Yu, Benjamin M. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2015138486-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | YU BENJAMIN M (US) | 2015-09-17 | — | — | WO | disclosed |
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | SPRAYABLE HOLDINGS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150250884-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | SPRAYABLE HOLDINGS, INC. | 2015-09-10 | — | — | US | disclosed |
| WO-2014138708-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORMS OF SOLUTION OR SUSPENSION | YU BENJAMIN M (US) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258065-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | MTNR1A, MTNR1B, CYP27B1 | PTGS2 741/4885PTGS1 809/4885CXCR1 1022/4885 |
| US-20150250884-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY | VDR, CYP27B1, TTPA | PTGS2 980/4885PTGS1 742/4885CXCR1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.